Soongyu Choi

Soongyu Choi is the co-CEO and co-founder of Avelos Therapeutics, a Seoul-based clinical-stage precision oncology company chasing first-in-class small molecules in synthetic lethality, DNA damage response, and cell cycle control. A Harvard-trained chemist who spent a decade at PTC Therapeutics and led R&D at Yuhan and Hana Pharm, he co-founded Avelos in 2021 and was elevated from CTO to co-CEO in January 2024. His flagship program, AD1208, is a first-in-class MASTL kinase inhibitor he frames as a precise strike on cancers that have stopped responding to standard therapy.